SCHEMBL2386613

SCHEMBL2386613

CC(C)(C)c1noc(N2CCC(CCCO)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.39
CYP11B2 P19099 1/20 0.38
ALOX5AP P20292 9/20 0.38
CDK4 P11802 2/20 0.33
CCND1 P24385 2/20 0.33
CCND2 P30279 2/20 0.33
CCND3 P30281 2/20 0.33
AKR1C3 P42330 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
LTA4H P09960 1/20 0.32
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
CHRM3 P20309 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
CCNE2 O96020 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713467 0.81 GPR119 (0.39) GPR119CYP11B2ALOX5APCDK4CCND1
SCHEMBL1103887 0.80 GPR119 (0.64) GPR119CYP11B2CNR2CHRM4
SCHEMBL356316 0.80 GPR119 (0.59) GPR119ALOX5APCNR2
SCHEMBL2394364 0.79 GPR119 (0.42) GPR119ALOX5APCNR2
SCHEMBL2427828 0.79 GPR119 (0.37) GPR119CYP11B2ALOX5APCDK4CCND1
SCHEMBL470684 0.78 GPR119 (0.47) GPR119ALOX5AP
SCHEMBL12490078 0.77 GPR119 (0.39) GPR119ALOX5AP
SCHEMBL2565338 0.76 CYP11B2 (0.43) CYP11B2CDK4CCND1CCND2CCND3
SCHEMBL14730237 0.74 HRH4 (0.39) GPR119ALOX5AP
SCHEMBL14730328 0.74 GPR119 (0.37) GPR119ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011128394-A1 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2011-10-20 WO disclosed
US-20110230507-A1 Piperidine GPCR Agonists PROSIDION LIMITED (GB) 2011-09-22 US disclosed
US-20110230507-A1 Piperidine GPCR Agonists PROSIDION LIMITED (GB) 2011-09-22 US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230507-A1 Piperidine GPCR Agonists GPR119, GPR27, GLP1R GPR119 1/4885CYP11B2 1400/4885ALOX5AP 1397/4885
US-20110212939-A1 Heterocyclic GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885CYP11B2 520/4885ALOX5AP 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.